Success Metrics

Clinical Success Rate
82.8%

Based on 48 completed trials

Completion Rate
83%(48/58)
Active Trials
2(3%)
Results Posted
63%(30 trials)
Terminated
10(14%)

Phase Distribution

Ph not_applicable
14
20%
Ph phase_4
14
20%
Ph phase_1
16
23%
Ph phase_3
11
16%
Ph phase_2
13
19%

Phase Distribution

16

Early Stage

13

Mid Stage

25

Late Stage

Phase Distribution68 total trials
Phase 1Safety & dosage
16(23.5%)
Phase 2Efficacy & side effects
13(19.1%)
Phase 3Large-scale testing
11(16.2%)
Phase 4Post-market surveillance
14(20.6%)
N/ANon-phased studies
14(20.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

77.4%

48 of 62 finished

Non-Completion Rate

22.6%

14 ended early

Currently Active

2

trials recruiting

Total Trials

69

all time

Status Distribution
Active(3)
Completed(48)
Terminated(14)
Other(4)

Detailed Status

Completed48
Terminated10
unknown4
Withdrawn4
Active, not recruiting2
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
69
Active
2
Success Rate
82.8%
Most Advanced
Phase 4

Trials by Phase

Phase 116 (23.5%)
Phase 213 (19.1%)
Phase 311 (16.2%)
Phase 414 (20.6%)
N/A14 (20.6%)

Trials by Status

active_not_recruiting23%
completed4870%
terminated1014%
unknown46%
withdrawn46%
enrolling_by_invitation11%

Recent Activity

Clinical Trials (69)

Showing 20 of 69 trialsScroll for more
NCT07568574Not Applicable

Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes

Enrolling By Invitation
NCT07547878Phase 4

Simultaneous Starting of the 4 Guideline Directed CKD Therapies (RAPID-CKD)

Active Not Recruiting
NCT04550481Phase 2

Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study

Active Not Recruiting
NCT05056727Phase 3

A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia

Terminated
NCT02847338Phase 4

Comparison of Optimal Hypertension Regimens

Completed
NCT03201939Phase 2

Optimal Management of HIV Infected Adults at Risk for Kidney Complications in Nigeria

Terminated
NCT06772779Phase 1

A Study of Enlicitide Decanoate (MK-0616), Warfarin, and Lisinopril in Healthy Adult Participants (MK-0616-026)

Completed
NCT03392740Phase 4

Prophylactic Lisinopril to Prevent Anthracycline Cardiomyopathy.

Withdrawn
NCT00006294

Genetics of Hypertension Associated Treatments (GenHAT)

Completed
NCT00430040Phase 4

Vascular Benefits of Adding CarvedilolCR to Type2 Diabetic Patients on ACEI.

Terminated
NCT00743197Not Applicable

Women With Chest Pain and Normal Coronary Arteries Study

Terminated
NCT04190433Phase 2

Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial

Withdrawn
NCT03422705Phase 2

A Pilot Study: Preventing Adverse Remodelling Following Pacemaker Implantation

Unknown
NCT03461003Phase 4

N-of-1 Trials In Children With Hypertension

Completed
NCT05016440Not Applicable

Lisinopril for Renal Protection in Postpartum Preeclamptic Women

Withdrawn
NCT01009918Phase 2

Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab

Completed
NCT01984164Phase 2

CAndesartan vs LIsinopril Effects on the BRain

Completed
NCT00874432Phase 2

Effect of ACE-inhibitors on Aortic Stiffness in Elderly Patients With Chronic Kidney Disease

Completed
NCT01837069Phase 4

Risk Factor Control Before Orthopedic Surgery

Terminated
NCT01885559Phase 3

HALT Progression of Polycystic Kidney Disease Study B

Completed

Drug Details

Intervention Type
DRUG
Total Trials
69